Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Nursing and Midwifery Department, Islamic Azad University, Najafabad Branch, Najafabad, Esfahan, Iran.
Curr Gene Ther. 2020;20(5):373-382. doi: 10.2174/1566523220666201012150130.
Ischemic stroke is one of the main causes of mortality in advanced societies. Although gene therapy can be helpful, delivering gene therapy agents is challenging. Nanotechnology can enhance the potential therapeutic effects and the efficiency of gene therapy for some brain disorders. The present systematic review was conducted based on the PRISMA protocol to investigate the possible therapeutic effects of nanoparticles as the carriers of gene therapy agents in stroke therapy. Relevant keywords were used to search from ISI Web of Science, PubMed, and Scopus for relevant publications up to April 24, 2020. The selected articles were assessed using certain scores on the quality of the articles. Data extraction and quality judgment were carried out by the present reviewers. Of 130 articles retrieved, seven met the inclusion criteria and were, therefore, included in the final analysis. The outcome of the reviewing process revealed that depending on the selection of the target genes, stroke gene therapies have acceptable therapeutic consequences. The nanoparticles could be used to carry the gene therapy agents that are efficient targeting in stroke treatment. Also, it appears that the use of nanoparticles such as PEGylation and PAMAM, can be a valuable option to intensify the efficiency and specific targeting of stroke location. In conclusion, due to the inability of brain regeneration and the importance of genes in stroke-related complications, gene therapy seems to be a suitable treatment strategy. The use of suitable nanoparticles for transportation ensures the efficiency and usefulness of this method.
缺血性脑卒中是先进社会人群死亡的主要原因之一。尽管基因治疗可能有帮助，但将基因治疗剂递送至脑部极具挑战性。纳米技术可以增强一些脑部疾病的基因治疗的潜在治疗效果和效率。本系统评价是基于 PRISMA 方案进行的，旨在研究纳米颗粒作为基因治疗剂载体在脑卒中治疗中的可能治疗效果。使用相关关键词从 ISI Web of Science、PubMed 和 Scopus 搜索了截至 2020 年 4 月 24 日的相关文献。使用特定的文章质量评分标准评估了所选文章。本研究的审查人员进行了数据提取和质量判断。在检索到的 130 篇文章中，有 7 篇符合纳入标准，因此被纳入最终分析。审查过程的结果表明，根据靶基因的选择，脑卒中基因治疗具有可接受的治疗效果。纳米颗粒可用于携带基因治疗剂，从而对脑卒中治疗进行有效靶向。此外，使用纳米颗粒（如 PEGylation 和 PAMAM）似乎是一种有价值的选择，可以提高脑卒中部位的效率和特异性靶向。总之，由于大脑再生能力有限，以及基因在脑卒中相关并发症中的重要性，基因治疗似乎是一种合适的治疗策略。使用合适的纳米颗粒进行运输可确保该方法的效率和实用性。
